Search
Propentofylline
go.drugbank.com/drugs/DB06479ExperimentalCategories: Compounds used in a research, industrial, or household settingDicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [L7982] Dicyclomine was granted FDA approval on 11 May 1950.[L7967]
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline possesses potent agonist activity on dopamine D2 receptors. … Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.
Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamideAnileridine
go.drugbank.com/drugs/DB00913ApprovedIllicitWithdrawnNarcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS.
Synonyms: N-β-(p-aminophenyl)ethylnormeperidine, N-(β-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidineTisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalIt was granted approval by FDA in August 2017 under the market name Kymriah. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent
Rumex acetosella whole
go.drugbank.com/drugs/DB14166ApprovedWithdrawnRumex acetosella whole allergenic extract is used in allergenic testing.
Rumex crispus top
go.drugbank.com/drugs/DB14167ApprovedWithdrawnRumex crispus top allergenic extract is used in allergenic testing.
Salix nigra bark
go.drugbank.com/drugs/DB14169ApprovedWithdrawnSalix nigra bark allergenic extract is used in allergenic testing.
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalbreast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).